In a phase I trial, the infusion of EGFRvIII-targeting CAR-T cells led to an adaptive immunosuppressive tumor response characterized by FOX3P+ Treg infiltration and the upregulation of immunosuppressive markers, including IDO-1, IL-10, PD-L1, and TGF-β [246]. The gene discussed is IL10; the disease is neoplasm.